Share this article

Prospective surveillance, prophylactic treatment and proactivity, and… problems solved?

Neil Piller
15 August 2022

Our lymphoedema and lymphatic failure detection strategies and tools are wide ranging, and have good reliability and accuracy. O!en, however, when they are used to assess the subclinical and early stages of lymphoedema, we may be missing out on a key piece of information (i.e. how did the limb/limbs present prior to the intervention), which can cause or contribute to the swelling, and what they were like prior to any clinically detectable lymphoedema by these tools. In an ideal situation, we should undertake a prospective surveillance of these patients ” ideally, all of them or at least those at highest risk of developing lymphoedema. For these patients, irrespective of the cancer treatment programme, they are about to go through prehabilitation, which may provide improved functional outcomes and improved awareness, and perhaps allow earlier recognition and management of lymphoedema risk factors, and sub-clinical changes by the patient and healthcare team (Stout et al, 2021).

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.